BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30426662)

  • 1. Inhibiting the urokinase-type plasminogen activator receptor system recovers STZ-induced diabetic nephropathy.
    Dal Monte M; Cammalleri M; Pecci V; Carmosino M; Procino G; Pini A; De Rosa M; Pavone V; Svelto M; Bagnoli P
    J Cell Mol Med; 2019 Feb; 23(2):1034-1049. PubMed ID: 30426662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal synthesis of urokinase type-plasminogen activator, its receptor, and plasminogen activator inhibitor-1 in diabetic nephropathy in rats: modulation by angiotensin-converting-enzyme inhibitor.
    Kenichi M; Masanobu M; Takehiko K; Shoko T; Akira F; Katsushige A; Takashi H; Yoshiyuki O; Shigeru K
    J Lab Clin Med; 2004 Aug; 144(2):69-77. PubMed ID: 15322501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The urokinase-type plasminogen activator system as drug target in retinitis pigmentosa: New pre-clinical evidence in the rd10 mouse model.
    Cammalleri M; Dal Monte M; Locri F; Pecci V; De Rosa M; Pavone V; Bagnoli P
    J Cell Mol Med; 2019 Aug; 23(8):5176-5192. PubMed ID: 31251468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetic Retinopathy in the Spontaneously Diabetic Torii Rat: Pathogenetic Mechanisms and Preventive Efficacy of Inhibiting the Urokinase-Type Plasminogen Activator Receptor System.
    Cammalleri M; Dal Monte M; Locri F; Marsili S; Lista L; De Rosa M; Pavone V; Rusciano D; Bagnoli P
    J Diabetes Res; 2017; 2017():2904150. PubMed ID: 29464181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of uPA on mesangial matrix changes in the kidney of diabetic rats.
    Cheng H; Chen C; Wang S
    Ren Fail; 2014 Sep; 36(8):1322-7. PubMed ID: 25010090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated β1-integrin endocytosis.
    Kobayashi N; Ueno T; Ohashi K; Yamashita H; Takahashi Y; Sakamoto K; Manabe S; Hara S; Takashima Y; Dan T; Pastan I; Miyata T; Kurihara H; Matsusaka T; Reiser J; Nagata M
    Am J Physiol Renal Physiol; 2015 Mar; 308(6):F614-26. PubMed ID: 25587125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urokinase-type Plasminogen Activator (uPA) Binding to the uPA Receptor (uPAR) Promotes Axonal Regeneration in the Central Nervous System.
    Merino P; Diaz A; Jeanneret V; Wu F; Torre E; Cheng L; Yepes M
    J Biol Chem; 2017 Feb; 292(7):2741-2753. PubMed ID: 27986809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy.
    Nicholas SB; Aguiniga E; Ren Y; Kim J; Wong J; Govindarajan N; Noda M; Wang W; Kawano Y; Collins A; Hsueh WA
    Kidney Int; 2005 Apr; 67(4):1297-307. PubMed ID: 15780082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Urokinase Receptor-Derived Peptide UPARANT Mitigates Angiogenesis in a Mouse Model of Laser-Induced Choroidal Neovascularization.
    Cammalleri M; Dal Monte M; Locri F; Lista L; Aronsson M; Kvanta A; Rusciano D; De Rosa M; Pavone V; André H; Bagnoli P
    Invest Ophthalmol Vis Sci; 2016 May; 57(6):2600–2611. PubMed ID: 27168367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal stem cells ameliorate podocyte injury and proteinuria in a type 1 diabetic nephropathy rat model.
    Wang S; Li Y; Zhao J; Zhang J; Huang Y
    Biol Blood Marrow Transplant; 2013 Apr; 19(4):538-46. PubMed ID: 23295166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of type-1 plasminogen activator inhibitor in the kidney of diabetic rat models.
    Hagiwara H; Kaizu K; Uriu K; Noguchi T; Takagi I; Qie YL; Seki T; Ariga T
    Thromb Res; 2003; 111(4-5):301-9. PubMed ID: 14693179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T; Behrendt N; Ploug M
    Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis.
    Lee JH; Oh MH; Park JS; Na GJ; Gil HW; Yang JO; Lee EY; Hong SY
    Korean J Intern Med; 2014 Mar; 29(2):176-82. PubMed ID: 24648800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Cross Talk between Neuronal Urokinase-type Plasminogen Activator (uPA) and Astrocytic uPA Receptor (uPAR) Promotes Astrocytic Activation and Synaptic Recovery in the Ischemic Brain.
    Diaz A; Merino P; Manrique LG; Ospina JP; Cheng L; Wu F; Jeanneret V; Yepes M
    J Neurosci; 2017 Oct; 37(43):10310-10322. PubMed ID: 28931568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of urokinase plasminogen activator/plasmin-mediated invasion of melanoma cells by the integrin vitronectin receptor alphaVbeta3.
    Khatib AM; Nip J; Fallavollita L; Lehmann M; Jensen G; Brodt P
    Int J Cancer; 2001 Feb; 91(3):300-8. PubMed ID: 11169951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db mice.
    Zhang L; Li R; Shi W; Liang X; Liu S; Ye Z; Yu C; Chen Y; Zhang B; Wang W; Lai Y; Ma J; Li Z; Tan X
    Br J Pharmacol; 2013 Sep; 170(2):426-39. PubMed ID: 23826864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased expression of plasminogen activator and plasminogen activator inhibitor during liver fibrogenesis of rats: role of stellate cells.
    Zhang LP; Takahara T; Yata Y; Furui K; Jin B; Kawada N; Watanabe A
    J Hepatol; 1999 Oct; 31(4):703-11. PubMed ID: 10551395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation.
    Tarui T; Akakura N; Majumdar M; Andronicos N; Takagi J; Mazar AP; Bdeir K; Kuo A; Yarovoi SV; Cines DB; Takada Y
    Thromb Haemost; 2006 Mar; 95(3):524-34. PubMed ID: 16525582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A peptide inhibitor of the urokinase/urokinase receptor system inhibits alteration of the blood-retinal barrier in diabetes.
    Navaratna D; Menicucci G; Maestas J; Srinivasan R; McGuire P; Das A
    FASEB J; 2008 Sep; 22(9):3310-7. PubMed ID: 18559877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Podocyte injury: the role of proteinuria, urinary plasminogen, and oxidative stress.
    Raij L; Tian R; Wong JS; He JC; Campbell KN
    Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1308-F1317. PubMed ID: 27335373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.